|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02637 HAIXI PHARMA
Nominal 
189.300 -0.400 (-0.211%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 311,619 | 3.847% | 582,358 | 466,683 | 316,633 | 212,465 |
| Cost of Sales | (56,462) | 39.018% | (96,801) | (79,489) | (52,994) | (40,393) |
| Gross Profit | 255,157 | -1.659% | 485,557 | 387,194 | 263,639 | 172,072 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 1,495 | -71.027% | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | 9 | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (8,120) | (7,834) | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 84,300 | -31.402% | 198,076 | 148,994 | 132,813 | 73,764 | |
| Taxation | (3,252) | -78.444% | (21,047) | (12,915) | (15,359) | (4,783) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 81,049 | -24.820% | 177,029 | 136,079 | 117,454 | 68,981 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 11,759 | 321.039% | (3,194) | 1,581 | 662 | 18,348 |
| Depreciation & Amortisation | 10,666 | 332.020% | 4,813 | 4,724 | 3,673 | 2,588 |
| Directors' Emoluments | -- | -- | -- | 3,185 | 2,961 | 2,408 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 103.000 | -35.625% | 255.000 | 202.000 | 175.000 | 107.000 |
| DPS (cts) | 0.000 | -- | 0.000 | -- | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 2.300 | 2.439 | 2.189 | 1.327 |
| NBV per share ($) | 21.208 | -- | 20.249 | -- | -- | -- |
| Remarks: | Real time quote last updated: 11/09/2026 10:23 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 81,049 |
| %Change | -24.820% |
| EPS / (LPS) | RMB 1.030 |
| NBV Per Share (¥) | RMB 21.208 |